Study Finds Vascepa Can Treat Severe Hypertriglyceridemia
A clinical trial conducted by biopharmaceutical company Amarin Corporation has found that Vascepa capsules can reduce lipoprotein particle concentration and size in patients with very high triglyceride levels. Known for short as the MARINE study (AMR101, a Pure EPA Omega-3 Fatty Acid: Effects on Lipoprotein Particle Concentration and Size in Patients with Very High Triglyceride Levels), the clinical trial was conducted on 229 patients over a period of 12 weeks. A Phase 3, multi-centre, placebo-controlled, randomised, double-blind study, the MARINE study found that the administering of Vascepa capsules to patients with baseline triglyceride levels noticeably reduced their median concentrations of lipoprotein particles, and particle size analysis also revealed smaller particles. The trial successfully achieved its primary efficacy end points, as defined in the clinical trial protocol, and also demonstrated a favourable safety profile. Amarin Corporation has since announced that additional data from the MARINE study can be obtained electronically through the Journal of Clinical Lipidology.